Marshall Wace’s Design Therapeutics DSGN Stock Holding History

Marshall Wace’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.61M	Sell	151,008 -74,520	-33%	-$754K	﹤0.01%	1908
2025 Q4	$2.12M	Buy	+225,528	New	+$1.77M	﹤0.01%	1550
2024 Q4	–	Sell	-17,192	Closed	-$92.5K	–	2673
2024 Q3	$92.5K	Sell	17,192 -7,088	-29%	-$33.3K	﹤0.01%	2382
2024 Q2	$81.3K	Buy	+24,280	New	+$94.6K	﹤0.01%	2406
2023 Q4	–	Sell	-60,542	Closed	-$143K	–	2262
2023 Q3	$143K	Sell	60,542 -52,380	-46%	-$244K	﹤0.01%	2013
2023 Q2	$711K	Sell	112,922 -67,997	-38%	-$416K	﹤0.01%	1856
2023 Q1	$1.04M	Buy	180,919 +68,101	+60%	+$509K	﹤0.01%	1791
2022 Q4	$1.16M	Buy	+112,818	New	+$1.53M	﹤0.01%	2023

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace's DSGN Position: Q1 2026 in Review

Marshall Wace reduced its Design Therapeutics (DSGN) stake by 33% in Q1 2026, selling an estimated $754K and leaving 151,008 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1908.

Marshall Wace first reported a position in DSGN in Q4 2022 and has held it in 8 quarters since. The position peaked at $2.12M in Q4 2025. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

Marshall Wace held 151,008 shares of Design Therapeutics worth $1.61M as of Q1 2026.
Marshall Wace sold 74,520 Design Therapeutics shares in Q1 2026, an estimated $754K.
Design Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1908 holding.
Marshall Wace first reported a position in Design Therapeutics in Q4 2022 and has held it in 8 quarters since.
Marshall Wace's Design Therapeutics position peaked at $2.12M in Q4 2025.
125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.